产品封面图
文献支持

HCC1954细胞

收藏
  • ¥3000
  • BHcell(博辉生物)
  • BH-C328
  • 2025年12月24日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    HCC1954/HCC1954细胞系/HCC1954细胞株/HCC1954人乳腺导管癌细胞

    Cell line name HCC1954

    Synonyms HCC-1954; Hamon Cancer Center 1954

    Accession CVCL_1259

    Resource Identification Initiative To cite this cell line use: HCC1954 (RRID:CVCL_1259)

    Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: JWGray breast cancer cell line panel.

    Part of: ICBP43 breast cancer cell line panel.

    Part of: KuDOS 95 cell line panel.

    Part of: MD Anderson Cell Lines Project.

    Population: East Indian.

    Doubling time: 45 hours (PubMed=25984343); 43.81 hours (JWGray panel).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Array-based CGH.

    Omics: H2BK120ub ChIP-seq epigenome analysis.

    Omics: H3K23ac ChIP-seq epigenome analysis.

    Omics: H3K27ac ChIP-seq epigenome analysis.

    Omics: H3K27me3 ChIP-seq epigenome analysis.

    Omics: H3K36me3 ChIP-seq epigenome analysis.

    Omics: H3K4me1 ChIP-seq epigenome analysis.

    Omics: H3K4me3 ChIP-seq epigenome analysis.

    Omics: H3K79me2 ChIP-seq epigenome analysis.

    Omics: H3K9ac ChIP-seq epigenome analysis.

    Omics: H3K9me3 ChIP-seq epigenome analysis.

    Omics: H4K8ac ChIP-seq epigenome analysis.

    Omics: CNV analysis.

    Omics: CRISPR phenotypic screen.

    Omics: Deep exome analysis.

    Omics: Deep quantitative proteome analysis.

    Omics: DNA methylation analysis.

    Omics: Glycoproteome analysis by proteomics.

    Omics: Hi-C chromosome conformation analysis.

    Omics: miRNA expression profiling.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: shRNA library screening.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Derived from site: In situ; Breast; UBERON=UBERON_0000310.

    Sequence variations

    Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (PubMed=23637631).

    Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (ATCC=CRL-2338).

    Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (PubMed=28889351; ATCC=CRL-2338).

    HLA typing Source: PubMed=25960936

    Class I

    HLA-A A*24:02,24:02

    HLA-B B*35:01,40:06

    HLA-C C*04:01,15:02

    Class II

    HLA-DQ DQA1*03:02,01:02

    HLA-DR DRB1*16:05,16:05

     

    Source: PubMed=26589293

    Class I

    HLA-A A*24:02,24:02

    HLA-B B*35:01,40:06

    HLA-C C*04:01,15:02

    Genome ancestry Source: PubMed=30894373

     

    Origin % genome

    African 0.47

    Native American 0

    East Asian, North 5.83

    East Asian, South 0

    South Asian 78.3

    European, North 2.65

    European, South 12.74

    Disease Breast ductal carcinoma (NCIt: C4017)

    Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

    Hierarchy Children:

    CVCL_LG20 (HCC1954-LR) CVCL_4W93 (HCC1954-Luc) CVCL_LG21 (HCC1954-NR)

    CVCL_VR24 (HCC1954-TGL) CVCL_B3MM (HCC1954/TDR)

    Originate from same individual CVCL_1260 ! HCC1954 BL

    Sex of cell Female

    Age at sampling 61Y

    Category Cancer cell line

    STR profile Source(s): ATCC=CRL-2338; Cosmic-CLP=749709; PubMed=25877200; PubMed=28889351; Technion Genomics Center

     

    Markers:

    Amelogenin X

    CSF1PO 10

    D1S1656 15,16

    D2S441 10,11

    D2S1338 17,26

    D3S1358 15,16

    D5S818 11

    D7S820 10,11

    D8S1179 12,15

    D10S1248 14,15

    D12S391 22

    D13S317 8,9

    D16S539 9,11

    D18S51 14,18

    D19S433 13,15.2

    D21S11 28,32.2

    D22S1045 11,15

    FGA 22,23

    Penta D 9,12

    Penta E 12,16

    TH01 6,7

    TPOX 8,9

    vWA 18,19

     

     

    PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L

    Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L.S., Sakaguchi M., Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I., Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.

    Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

    Int. J. Cancer 78:766-774(1998)

     

    PubMed=11314036; DOI=10.1038/sj.onc.1204211

    Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.

    Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

    Oncogene 20:1005-1009(2001)

     

    PubMed=16959974; DOI=10.1126/science.1133427

    Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.E., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.-S., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.

    The consensus coding sequences of human breast and colorectal cancers.

    Science 314:268-274(2006)

     

    PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521

    Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

    A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

    Cancer Cell 10:515-527(2006)

     

    PubMed=17932254; DOI=10.1126/science.1145720

    Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T.D., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z.-M., Croshaw R., Willis J.E., Dawson D., Shipitsin M., Willson J.K.V., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V.K., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., Vogelstein B.

    The genomic landscapes of human breast and colorectal cancers.

    Science 318:1108-1113(2007)

     

    PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084

    Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.

    Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

    PLoS ONE 4:E6146-E6146(2009)

     

    PubMed=20070913; DOI=10.1186/1471-2407-10-15; PMCID=PMC2836299

    Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.

    Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

    BMC Cancer 10:15.1-15.10(2010)

     

    PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

    Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

    Cancer Res. 70:2158-2164(2010)

     

    PubMed=21378333

    Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.

    Reassessment of estrogen receptor expression in human breast cancer cell lines.

    Anticancer Res. 31:521-527(2011)

     

    PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396

    Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.

    Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

    Cancer Discov. 2:172-189(2012)

     

    PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428

    Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.

    Molecular characterisation of cell line models for triple-negative breast cancers.

    BMC Genomics 13:619.1-619.14(2012)

     

    PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661

    Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.

    miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

    Breast Cancer Res. 15:R33.1-R33.17(2013)

     

    PubMed=23637631; DOI=10.1371/journal.pgen.1003464; PMCID=PMC3636093

    Giacomini C.P., Sun S., Varma S., Shain A.H., Giacomini M.M., Balagtas J.M.S., Sweeney R.T., Lai E., Del Vecchio C.A., Forster A.D., Clarke N., Montgomery K.D., Zhu S., Wong A.J., van de Rijn M., West R.B., Pollack J.R.

    Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.

    PLoS Genet. 9:E1003464-E1003464(2013)

     

    PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310

    Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.

    Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

    Cancer Cell 24:450-465(2013)

     

    PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776

    Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.

    Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

    Breast Cancer Res. Treat. 142:237-255(2013)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.

    相关实验
    • 肿瘤领域研究方向之肿瘤治疗与耐药

      学问题。 案例一:多组学分析揭示肝癌起始细胞免疫逃逸机制和精准治疗策略 发表期刊:Cancer Cell 影响因子:44.5 发表时间:2024 年 12 月 研究疾病:肝细胞癌(Hepatocellular Carcinoma,HCC) 样本类型:患者来源的肝癌类器官(HCC organoids),肝癌细胞系(Hep3B,Huh7,PLC/PRF/5, MHCC97 H,Hep53.4)和小鼠模型(包括自发性肝癌模型和异种移植模型) 样本数量:11 个 HCC 类器官样本,4 个肝癌细胞系样本

    • 文献速递:全面液体分析循环肿瘤DNA和蛋白质生物标志物为评估预后带来新的可能

      研究背景 肝细胞癌(HCC)被认为是中国癌症相关死亡率的第三大原因。尽管手术是治疗HCC的较佳选择,但由于缺乏早期症状,大多数患者在癌症晚期才被诊断出来,因此肿瘤复发的风险很高。识别可能复发的患者并给予对应的辅助治疗,仍然是一个临床难题。循环肿瘤DNA(ctDNA),也可称为肿瘤衍生的细胞游离DNA,包含有关肿瘤基因组图谱的全面信息,包括单核苷酸变异(SNVs)、拷贝数变异(CNVs)和表观遗传变异。将ctDNA与HCC中的传统血清蛋白生物标志物结合将为无创监测实时肿瘤进展提供新的可能。  

    • 细胞测序技术之肝细胞相关实验方案策略

      细胞癌(HCC)是肝癌的主要组织学亚型,占原发性肝癌的 90%,是全世界癌症相关死亡率的第三大常见原因。肝癌的诱因诸多,譬如遗传、表观遗传改变、慢性乙型肝炎、肥胖和糖尿病等都是肝癌的主要危险因素,而且肝癌预后差,复发率和转移率高。因此本篇应用单细胞测序技术研究案例分享以孙倍成教授带领其研究团队发表在国际免疫学顶级期刊 Immunity 上的肝癌(HCC)炎癌转化调控新机制说起! 1.文章介绍 论著题目:The zinc finger protein Miz1 suppresses liver

    图标技术资料

    资料下载:

    HCC1954(BH-C328).docx 附 (下载 0 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥900
    上海泽叶生物科技有限公司
    2026年01月04日询价
    询价
    上海沪震实业有限公司
    2025年12月31日询价
    ¥900
    上海淳麦生物科技有限公司
    2025年07月10日询价
    ¥2500
    镜像绮点(上海)细胞技术有限公司
    2026年01月06日询价
    ¥1800
    上海匹拓生物科技有限公司
    2025年12月19日询价
    文献支持
    HCC1954细胞
    ¥3000